Opinion|Videos|July 26, 2024
Considerations in Sequencing BCMA-Targeting Bispecifics and CAR-T Therapies in R/R MM
Myeloma specialists discuss considerations they consider when determining how they sequence CAR T-cell therapies and bispecific antibodies.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Can BCMA-targeting bispecifics be used in patients who have received prior BCMA-targeting CAR-T therapies?
- Might you consider a different target?
- Might you consider a different target?
Advertisement
Related to this article
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
Advertisement
Advertisement
Trending on CancerNetwork
1
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
2
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
3
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer
4
What Were the Key Hematologic Oncology Takeaways from SOHO 2026?
5